AstraZeneca PLC filings document the disclosures of a foreign private issuer focused on prescription medicines across oncology, rare diseases, cardiovascular, renal and metabolism, respiratory, and immunology. The company’s Form 6-K reports include quarterly operating results, product sales, alliance and collaboration revenue, EPS measures, and management commentary on medicine performance and pipeline progress.
Other filings record FDA advisory-committee and approval updates for medicines such as TRUQAP, BREZTRI, SAPHNELO, camizestrant, and ULTOMIRIS; Phase III trial disclosures; licensing arrangements; Board changes; total voting rights; and admission of additional ordinary shares. These documents also provide capital-structure and governance information relevant to AstraZeneca’s UK issuer framework and SEC foreign-issuer reporting obligations.
AstraZeneca PLC has published its Notice of Annual General Meeting 2026 and shareholders’ circular and is dispatching them to shareholders. The digitally-enabled AGM will be held on 9 April 2026 at 14:30 (BST).
Shareholders will vote on receiving the 2025 accounts, confirming 2025 interim dividends, appointing KPMG LLP as auditor, re-electing directors, approving the remuneration report, renewing authority for the 2020 Performance Share Plan French appendix, authorising political donations, allotting shares, disapplying pre-emption rights, authorising share buybacks, and reducing the notice period for general meetings. The Notice and related documents are available on AstraZeneca’s website and via the UK National Storage Mechanism.
AstraZeneca PLC reported that Chief Executive Officer Pascal Soriot received ordinary shares following the vesting of a long-term incentive award under the AstraZeneca Performance Share Plan (AZPSP).
The AZPSP award, granted on 5 March 2021 with a three-year performance period and subsequent two-year holding period, vested on its fifth anniversary. Application of the original performance conditions led to 88% of the award vesting and the remainder lapsing. After dividend reinvestment and withholding of shares to cover tax obligations, Soriot acquired 101,495 ordinary shares on 5 March 2026 for nil consideration. For tax purposes, the fair market value at vest was 15,088 pence per share, based on the closing price on the previous trading day.
AstraZeneca PLC reported that share awards granted under its AstraZeneca Deferred Bonus Plan for 2022 performance vested on 4 March 2026 for senior executives. These awards reflect portions of prior annual bonuses that were deferred into ordinary shares and held for a three-year period.
On vesting, Chief Executive Officer Pascal Soriot acquired 14,967 ordinary shares and Chief Financial Officer Aradhana Sarin acquired 4,863 ordinary shares, both for nil consideration. For tax purposes, the fair market value at vest was 14,932 pence per ordinary share, based on the closing price on the last trading day before vesting.
AstraZeneca PLC reported that on 4 March 2026 it granted share awards to its Chief Executive Officer and Chief Financial Officer under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan.
Pascal Soriot received 13,970 Ordinary Shares under the deferred bonus plan and 89,611 under the performance share plan, at an award price of £152.42 per share. Aradhana Sarin received 5,258 Ordinary Shares under the deferred bonus plan and 37,135 under the performance share plan, also at £152.42 per share.
The deferred bonus awards represent required deferrals of each executive’s 2025 annual bonus into shares and are due to vest after a three-year holding period. The performance share awards are subject to scientific, commercial, financial and sustainability performance measures assessed from 1 January 2026 to 31 December 2028 and then a further two-year holding period, vesting on the fifth anniversary of grant.
AstraZeneca PLC reports the issuance by its subsidiary AstraZeneca Finance LLC of three new U.S. dollar fixed rate note tranches, fully and unconditionally guaranteed by AstraZeneca PLC. These consist of $650,000,000 4.000% notes due 2031, $600,000,000 4.300% notes due 2033, and $750,000,000 4.600% notes due 2036.
The company is furnishing this information so the related underwriting, pricing, officer certificates, and legal opinions can be incorporated into its existing shelf registration statement on Form F-3.
AstraZeneca PLC reports its current voting share capital. As at 28 February 2026, the company has 1,550,966,708 issued ordinary shares of US$0.25 each with voting rights, and no shares held in treasury. This means the total number of voting rights is 1,550,966,708.
Shareholders can use this total voting rights figure as the denominator when calculating whether they must notify the UK Financial Conduct Authority of holdings or changes in their interest under the Disclosure and Transparency Rules.
AstraZeneca PLC has priced a $2bn global bond offering through its wholly owned subsidiary AstraZeneca Finance LLC. The bonds are issued in three fixed-rate tranches registered with the U.S. SEC and are fully and unconditionally guaranteed by AstraZeneca.
The tranches comprise $0.65bn of notes with a 4.000% coupon maturing on 2 March 2031, $0.60bn with a 4.300% coupon maturing on 2 March 2033, and $0.75bn with a 4.600% coupon maturing on 2 March 2036.
AstraZeneca expects to use the net proceeds for general corporate purposes, which may include refinancing existing debt. The company states that this bond issuance does not impact its financial guidance for 2026.
AstraZeneca PLC has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission. The report can be viewed on both the SEC website and the company’s own site, giving investors access to detailed audited financial and business information.
The company will provide any security holder with a hard copy of its complete audited financial statements free of charge upon request through its Company Secretary in Cambridge, UK.